Raymond James Financial Inc. Acquires New Shares in Xencor, Inc. (NASDAQ:XNCR)

Raymond James Financial Inc. bought a new position in shares of Xencor, Inc. (NASDAQ:XNCR) during the 4th quarter, HoldingsChannel reports. The firm bought 101,346 shares of the biopharmaceutical company’s stock, valued at approximately $2,329,000.

Other large investors have also recently made changes to their positions in the company. Point72 Asset Management L.P. boosted its stake in Xencor by 147.3% during the third quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company’s stock valued at $62,748,000 after buying an additional 1,858,440 shares during the period. Geode Capital Management LLC boosted its position in shares of Xencor by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company’s stock valued at $29,273,000 after acquiring an additional 17,658 shares during the last quarter. Baker BROS. Advisors LP grew its holdings in shares of Xencor by 22.9% during the third quarter. Baker BROS. Advisors LP now owns 670,431 shares of the biopharmaceutical company’s stock worth $13,482,000 after purchasing an additional 125,000 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Xencor by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 630,640 shares of the biopharmaceutical company’s stock worth $14,492,000 after purchasing an additional 3,652 shares during the last quarter. Finally, RTW Investments LP purchased a new stake in Xencor in the third quarter valued at approximately $11,563,000.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on XNCR. StockNews.com cut shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Wells Fargo & Company lowered their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Finally, Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $20.00 to $30.00 in a report on Monday, December 2nd. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.38.

Xencor Stock Down 2.4 %

Shares of NASDAQ:XNCR opened at $11.23 on Friday. The stock’s 50-day moving average is $15.56 and its 200 day moving average is $20.09. The company has a market cap of $791.29 million, a PE ratio of -3.51 and a beta of 0.74. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor, Inc. has a 1 year low of $10.90 and a 1 year high of $27.24.

Xencor (NASDAQ:XNCR) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.19. The firm had revenue of $52.79 million for the quarter, compared to analysts’ expectations of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. Sell-side analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.